RalGAPbeta: A Potential Drug Target for Neurological Disorders

Target Name: RALGAPB

NCBI ID: G57148

RALGAPB

RalGAPbeta: A Potential Drug Target for Neurological Disorders

RALGAPB (RalGAPbeta) is a protein that is expressed in the brain and is known for its role in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time. It is also known to play a role in the development and progression of several neurological disorders, including Alzheimer's disease.

Recent studies have suggested that RalGAPbeta may be a drug target or biomarker for the treatment of these disorders. One potential mechanism by which RalGAPbeta may be targeted is through its role in the regulation of neurotransmitter release, which is the process by which the brain communicates with its muscles, neurons, and other cells.

Research has shown that changes in the levels of neurotransmitters, such as dopamine and glutamate, can contribute to the development and progression of neurological disorders. RalGAPbeta has been shown to regulate the release of these neurotransmitters, which suggests that it may play a role in the regulation of brain function and the development of neurological disorders.

In addition to its role in neurotransmitter regulation, RalGAPbeta has also been shown to be involved in the development and progression of neurodegenerative disorders. Studies have shown that RalGAPbeta is expressed in the brains of individuals with Alzheimer's disease, and that its levels are decreased in the brains of individuals with the disease.

These findings suggest that RalGAPbeta may be a potential drug target or biomarker for the treatment of Alzheimer's disease and other neurological disorders. Further research is needed to fully understand the role of RalGAPbeta in these disorders and to develop effective treatments.

Protein Name: Ral GTPase Activating Protein Non-catalytic Subunit Beta

Functions: Non-catalytic subunit of the heterodimeric RalGAP1 and RalGAP2 complexes which act as GTPase activators for the Ras-like small GTPases RALA and RALB

The "RALGAPB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RALGAPB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets